Pokorny Adrian M J, Bero Lisa A, Moynihan Raymond, Mintzes Barbara J
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Department of Medical Oncology, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
Intern Med J. 2021 Nov;51(11):1816-1824. doi: 10.1111/imj.15005. Epub 2021 Oct 22.
Payments to medical oncologists and clinical haematologists can negatively affect prescribing practice, but the extent of payments to these specialists is unknown in Australia.
To analyse the extent of payments from the pharmaceutical industry to Australian cancer physicians as reported during the first collated period of the Disclosure Australia website.
We performed a retrospective, cross-sectional analysis of payments made from November 2018 to April 2019, using a file downloaded from the Disclosure Australia website. We checked the names of listed medical practitioners against Medical Board of Australia records to assign specialties. The number of medical oncologists, clinical haematologists, other specialist physicians and non-specialist physician medical practitioners was calculated, along with the payments to each of these groups.
A total of A$7 332 407 was paid to 2775 medical practitioners. Of these, 236 were medical oncologists, 189 were haematologists and 1145 were other specialist physicians. This represents 31.7% of Australian medical oncologists and 30.9% of Australian haematologists, compared with 11.7% of all other specialist physicians and 1.1% of all other non-specialist physician medical practitioners. Medical oncologists received significantly higher payments (median A$2131.26) than other specialist physicians (median A$1376.00, 2-tailed P = 0.004) and other medical practitioners (median A$709.00, 2-tailed P < 0.001), while haematologists received significantly higher payments (median A$1519.95) than other medical practitioners (2-tailed P < 0.001), but similar payments to other specialist physicians (2-tailed P = 0.08).
Australian cancer physicians receive payments at a higher proportional frequency and in greater dollar amounts than other specialist physicians and other medical practitioners in general.
向肿瘤内科医生和临床血液科医生支付报酬可能会对处方行为产生负面影响，但在澳大利亚，向这些专科医生支付报酬的程度尚不清楚。
分析澳大利亚药品行业向癌症医生支付报酬的程度，该数据来自澳大利亚披露网站的首个整理期。
我们使用从澳大利亚披露网站下载的文件，对2018年11月至2019年4月期间的支付情况进行了回顾性横断面分析。我们对照澳大利亚医学委员会的记录检查列出的医生姓名，以确定其专业。计算了肿瘤内科医生、临床血液科医生、其他专科医生和非专科医生的人数，以及向这些群体的支付金额。
总共向2775名医生支付了7332407澳元。其中，236名是肿瘤内科医生，189名是血液科医生，1145名是其他专科医生。这分别占澳大利亚肿瘤内科医生的31.7%和澳大利亚血液科医生的30.9%，而在所有其他专科医生中占11.7%，在所有其他非专科医生中占1.1%。肿瘤内科医生获得的报酬（中位数为2131.26澳元）显著高于其他专科医生（中位数为1376.00澳元，双侧P = 0.004）和其他医生（中位数为709.00澳元，双侧P < 0.001），而血液科医生获得的报酬（中位数为1519.95澳元）显著高于其他医生（双侧P < 0.001），但与其他专科医生的报酬相似（双侧P = 0.08）。
总体而言，澳大利亚癌症医生获得报酬的比例更高，金额也比其他专科医生和其他医生更多。
